Journal of clinical gastroenterology · 2025
The Efficacy of Single Dose Linaclotide in Polyethylene Glycol-Based Bowel Preparation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Yizhong, Grieme Alexander, Liu Kyle S, Nguyen Vincent, Adamson Colby, Garza Manuel, Smith Eric R, Ramai Daryl, Han Andrew, Bushe Bryce, Adler Douglas G
Аннотация
INTRODUCTION: Adjunct agents in bowel preparation for colonoscopy have the potential to improve procedure outcomes. We performed a systematic review and meta-analysis to investigate the effects of adjunct single-dose linaclotide with bowel prep on colonoscopy outcomes.
METHODS: We conducted a comprehensive search in PubMed, Embase, Cochrane, and Web of Science from inception until April 2025 for randomized controlled trials comparing single-dose linaclotide adjunct bowel prep and standard bowel prep. Our pooled data was analyzed for adenoma detection rates (ADR), polyp detection rates (PDR), bowel prep quality, adverse reactions, and other secondary outcomes. A random effects model was used, and the data was presented using pooled odds ratios (OR) and mean differences (MD) with 95% CI.
RESULTS: Seven manuscripts were included with 2209 patients (1267 in the linaclotide group and 942 in the control group). The linaclotide group had a significantly higher ADR (OR: 1.31, 95% CI: 1.04-1.64, P =0.02, I2 0%) and PDR (OR: 1.43, 95% CI: 1.13-1.80, P =0.003, I2 0%). Adequate prep was higher in the linaclotide group among patients with diagnosed constipation ( P =0.002). The linaclotide group had a lower incidence of abdominal pain ( P =0.0009), bloating ( P =0.0006), and sleep disturbance ( P =0.002).
CONCLUSION: Linaclotide used as a single dose adjunct to bowel prep before colonoscopy increased ADR and PDR. Adequate prep was higher with linaclotide in patients with diagnosed constipation. Linaclotide also decreased the odds of abdominal pain, bloating, and sleep disturbances.
METHODS: We conducted a comprehensive search in PubMed, Embase, Cochrane, and Web of Science from inception until April 2025 for randomized controlled trials comparing single-dose linaclotide adjunct bowel prep and standard bowel prep. Our pooled data was analyzed for adenoma detection rates (ADR), polyp detection rates (PDR), bowel prep quality, adverse reactions, and other secondary outcomes. A random effects model was used, and the data was presented using pooled odds ratios (OR) and mean differences (MD) with 95% CI.
RESULTS: Seven manuscripts were included with 2209 patients (1267 in the linaclotide group and 942 in the control group). The linaclotide group had a significantly higher ADR (OR: 1.31, 95% CI: 1.04-1.64, P =0.02, I2 0%) and PDR (OR: 1.43, 95% CI: 1.13-1.80, P =0.003, I2 0%). Adequate prep was higher in the linaclotide group among patients with diagnosed constipation ( P =0.002). The linaclotide group had a lower incidence of abdominal pain ( P =0.0009), bloating ( P =0.0006), and sleep disturbance ( P =0.002).
CONCLUSION: Linaclotide used as a single dose adjunct to bowel prep before colonoscopy increased ADR and PDR. Adequate prep was higher with linaclotide in patients with diagnosed constipation. Linaclotide also decreased the odds of abdominal pain, bloating, and sleep disturbances.